Srini Akkaraju Akkaraju
Vorsitzender bei JIYA ACQUISITION CORP.
Vermögen: 13 597 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Richard D. van Doren | M | 47 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Theia Therapeutics, Inc.
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | 8 Jahre |
Perry Karsen | M | 69 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | 4 Jahre |
Eric Dobmeier | M | 55 |
Chinook Therapeutics U.S., Inc.
Chinook Therapeutics U.S., Inc. Information Technology ServicesTechnology Services Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA. | 4 Jahre |
Sanjay Shukla | M | 52 | 8 Jahre | |
Cory Freedland | M | 48 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Tentarix Biotherapeutics, Inc.
| 7 Jahre |
Michael Dybbs | M | 49 |
Samsara BioCapital LP
Samsara BioCapital LP Investment ManagersFinance Samsara Biocapital LP invests in companies located in the US. The fund targets companies operating in the fields of biotechnology and pharmaceuticals. It provides financing for early stage capital requirements.
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
565 SPV I LP
565 SPV I LP Investment ManagersFinance 565 SPV I LP provides investment services. The company is headquartered in Palo Alto, CA.
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group. | 15 Jahre |
Timothy Kutzkey | M | 49 |
Stanford University
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | 5 Jahre |
Glenn Sblendorio | M | 68 | 10 Jahre | |
Jay Backstrom | M | 69 | 2 Jahre | |
Dolca Thomas | M | 53 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 Jahre |
Amir Nashat | M | 51 |
Dewpoint Therapeutics, Inc.
Dewpoint Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dewpoint Therapeutics, Inc. develops drugs. The company is headquartered in Boston, MA. | 10 Jahre |
Jerel Davis | M | 47 |
Tentarix Biotherapeutics, Inc.
| 6 Jahre |
Conley Chee | M | 54 | 3 Jahre | |
David Guyer | M | 64 |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | 3 Jahre |
Rajiv Doshi | M | - |
Piper Biosciences, Inc.
Piper Biosciences, Inc. Pharmaceuticals: OtherHealth Technology Piper Biosciences, Inc. manufactures and sells cholesterol-lowering gummies with plant sterols. It offers cholesterol wellness kits.The company was founded by Rajiv Doshi and is headquartered in Los Altos, CA. | - |
Alexander G. Asam | M | 58 | 3 Jahre | |
Stephen MacMahon | M | - |
The George Institute for Global Health
The George Institute for Global Health Miscellaneous Commercial ServicesCommercial Services The George Institute for Global Health provides research and development for international health. It develops tools to empower people to improve their own health. The firm also uses mobile technology to make healthcare accessible worldwide and improves outcomes among stroke survivors. It helps preventing complications of diabetes. The company was founded by Stephen MacMahon and Robyn Norton in 1999 and is headquartered in Sydney, Australia. | 25 Jahre |
Karen Hunady | F | - | 2 Jahre | |
Katie Peng | F | - | - | |
Eliot Charles | M | 62 |
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group.
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | 7 Jahre |
Noopur Liffick | F | - | 4 Jahre | |
Roger Zhang | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 Jahre |
Andrew Oh | M | 53 | 2 Jahre | |
Adam Levy | M | 46 | 2 Jahre | |
Derek DiRocco | M | 43 | 2 Jahre | |
Richard Brudnick | M | 67 | 1 Jahre | |
Deborah Dunsire | M | 61 | 3 Jahre | |
Tim Tyson | M | 71 | 2 Jahre | |
Mani Subramanian | M | - |
OrsoBio Inc
OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation.
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 Jahre |
Tim Coughlin | M | 57 | 7 Jahre | |
Robert Stein | M | 73 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | 6 Jahre |
Daphne Karydas | F | 49 | 1 Jahre | |
S. Gail Eckhardt | M | 66 | 4 Jahre | |
Olivier Litzka | M | 56 | 2 Jahre | |
Murari Srinivasan | M | - |
Codex Health, Inc.
Codex Health, Inc. Packaged SoftwareTechnology Services Codex Health, Inc. is a company based in Palo Alto, CA. Codex Health specializes in disease management with AI-powered clinical intelligence. The company's products enable healthcare organizations to deliver better outcomes, reduce costs, and improve the overall patient experience. Codex Health, Inc. offers a modern approach to chronic disease management, providing personalized care that is seamlessly linked to the patient's care team. Codex Health also offers next-generation population health management, equipping patients with personalized experiences and supporting them in their self-care journey. The company provides targeted proactive care, identifying at-risk patients and managing them proactively to mitigate adverse events. Codex Health's solutions enable scalable continuous and asynchronous care, extending clinical care into the patient's daily life. The company also helps healthcare systems maximize revenue by optimizing patients' outcomes based on deep clinical and operational visibility into risk and outcomes. The company was founded by Murari Srinivasan and Srinivas Akkaraju, with Murari Srinivasan serving as the CEO since incorporation. | - |
Steve Kelsey | M | 63 | 4 Jahre | |
Nils Lonberg | M | 68 |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | - |
Dan Spiegelman | M | 65 | 4 Jahre | |
Stephen Shuttleworth | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | 5 Jahre |
Sushma Gambhir | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 Jahre |
Levi Smith | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 3 Jahre |
Jessica Ibbitson | F | - | 3 Jahre | |
Sarah Milsom | F | - |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | 3 Jahre |
Jason Haas | M | 56 | 3 Jahre | |
Rocco Venezia | M | 48 | 8 Jahre | |
Indrani Rebbapragada | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 2 Jahre |
Meysis Lam | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 3 Jahre |
Minji Kim | M | - | - | |
Abraham Bassan | M | 39 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 7 Jahre |
Mohammed Qatanani | M | 50 | 2 Jahre | |
Ravichandran Rao | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 2 Jahre |
Tracey Sacco | F | 47 | 1 Jahre | |
Marcos Milla | M | 61 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 3 Jahre |
Betsy Santos | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 2 Jahre |
Brady Johnson | M | - |
Tentarix Biotherapeutics LP
Tentarix Biotherapeutics LP BiotechnologyHealth Technology Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA. | 2 Jahre |
Miran Ahmad | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 2 Jahre |
Donald Jones | M | - |
Codex Health, Inc.
Codex Health, Inc. Packaged SoftwareTechnology Services Codex Health, Inc. is a company based in Palo Alto, CA. Codex Health specializes in disease management with AI-powered clinical intelligence. The company's products enable healthcare organizations to deliver better outcomes, reduce costs, and improve the overall patient experience. Codex Health, Inc. offers a modern approach to chronic disease management, providing personalized care that is seamlessly linked to the patient's care team. Codex Health also offers next-generation population health management, equipping patients with personalized experiences and supporting them in their self-care journey. The company provides targeted proactive care, identifying at-risk patients and managing them proactively to mitigate adverse events. Codex Health's solutions enable scalable continuous and asynchronous care, extending clinical care into the patient's daily life. The company also helps healthcare systems maximize revenue by optimizing patients' outcomes based on deep clinical and operational visibility into risk and outcomes. The company was founded by Murari Srinivasan and Srinivas Akkaraju, with Murari Srinivasan serving as the CEO since incorporation. | 2 Jahre |
Jing Marantz | M | 59 | 2 Jahre | |
Ken A. Brameld | M | 51 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 3 Jahre |
Thomas Hanke | M | - |
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | - |
Donald Santel | M | 62 |
Tentarix Biotherapeutics LP
Tentarix Biotherapeutics LP BiotechnologyHealth Technology Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA. | 2 Jahre |
Marie Coffman | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Sanj Patel | M | 54 | 4 Jahre | |
Al Altomari | M | 65 |
Barrier Therapeutics, Inc.
Barrier Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Barrier Therapeutics, Inc. discovers, develops, and commercializes pharmaceutical products in the field of dermatology in the United States. It markets Xolegel, Vusion, and Solage gels. The firm markets its products to dermatologists and other target physicians through sales force. The company was founded in 2001 and is headquartered in Princeton, NJ | 8 Jahre |
Nagesh Mahanthappa | M | 59 | 1 Jahre | |
Geert Cauwenbergh | M | 70 |
Barrier Therapeutics, Inc.
Barrier Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Barrier Therapeutics, Inc. discovers, develops, and commercializes pharmaceutical products in the field of dermatology in the United States. It markets Xolegel, Vusion, and Solage gels. The firm markets its products to dermatologists and other target physicians through sales force. The company was founded in 2001 and is headquartered in Princeton, NJ | 7 Jahre |
Gerald Quirk | M | 56 | 6 Jahre | |
Steven M. Leventer | M | 68 | 2 Jahre | |
Alex Kunczynski | M | - |
Stanford University
| 5 Jahre |
Lawrence S. Malkin | M | - |
Stanford University
| 4 Jahre |
Mauria Finley | F | 50 |
Stanford University
| 5 Jahre |
Chih-Kong Ken Yang | M | - |
Stanford University
| 5 Jahre |
Cipora Herman | F | 50 |
Stanford University
| 5 Jahre |
Rekha Hemrajani | F | 54 | 2 Jahre | |
Douglas Flanzer | M | - |
Stanford University
| 5 Jahre |
Jon Koplin | M | - |
Stanford University
| 5 Jahre |
Adam Nash | M | - |
Stanford University
| 5 Jahre |
Lori Friedman | M | 60 | - | |
Takeshi Takahashi | M | 48 | 3 Jahre | |
Jené Elzie | F | 50 |
Stanford University
| 5 Jahre |
Van Ton-Quinlivan | M | - |
Stanford University
| 2 Jahre |
Patrick Yue | M | - |
Stanford University
| 5 Jahre |
Teresa Kong | F | - |
Stanford University
| 5 Jahre |
Sameer Dholakia | M | 50 |
Stanford University
| 4 Jahre |
Sajal Srivastava | M | 48 |
Stanford University
| 4 Jahre |
Kay Luo | F | - |
Stanford University
| 6 Jahre |
Robert Neivert | M | - |
Stanford University
| 3 Jahre |
Sasa Zorovic | M | - |
Stanford University
| 6 Jahre |
David Lam | M | - |
Stanford University
| 5 Jahre |
Christopher C. Goodnow | M | - |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 8 Jahre |
Laura Shawver | M | 66 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 8 Jahre |
Alex Scherbakovsky | M | - |
Stanford University
| 4 Jahre |
Kenneth Lin | M | 51 |
Stanford University
Panorama Capital LLC
Panorama Capital LLC Investment ManagersFinance Panorama Capital LLC (Panorama Capita) is a venture capital firm founded in 1995 by Chris Albinson, Rod Ferguson, Shahan Soghikian and damion wicker. The firm is headquartered in Campbell, California. | 4 Jahre |
Eric Selmon | M | - |
Stanford University
| 5 Jahre |
Kevin Efrusy | M | 51 |
Stanford University
| 5 Jahre |
Jason Terrance Holzer | M | 52 |
Stanford University
| 4 Jahre |
Peter G. Schultz | M | 67 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | - |
Hans-Peter Guler | M | 75 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 6 Jahre |
Tim Roughgarden | M | - |
Stanford University
| 5 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 96 | 96,97% |
Vereinigtes Königreich | 3 | 3,03% |
Australien | 1 | 1,01% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Srini Akkaraju Akkaraju
- Persönliches Netzwerk